Background and aims: Studies examining the next‐day cognitive effects of heavy alcohol consumption have produced mixed findings, which may reflect inconsistencies in definitions of ‘hangover’. Recent consensus has defined hangover as ‘mental and physical symptoms, experienced the day after a single episode of heavy drinking, starting when blood alcohol concentration (BAC) approaches zero’. In light of this, we aimed to review the literature systematically to evaluate and estimate mean effect sizes of the next‐day effects of heavy alcohol consumption on cognition.Methods: Embase, PubMed and PsycNET databases were searched between December 2016 and May 2018 using terms based on ‘alcohol’ and ‘hangover’. Studies of experimental designs which reported the next‐day cognitive effects of heavy alcohol consumption in a ‘hangover’ group with BAC < 0.02% were reviewed. A total of 805 articles were identified. Thirty‐nine full‐text articles were screened by two independent reviewers and 19 included in the systematic review; 11 articles provided sufficient data to be included in the meta‐analysis; 1163 participants across 19 studies conducted since 1970 were included in the analysis. Data for study design, hangover severity, BAC at testing and cognitive performance were extracted and effect estimates calculated.Results: The systematic review suggested that sustained attention and driving abilities were impaired during hangover. Mixed results were observed for: psychomotor skills, short‐ (STM) and long‐term memory (LTM) and divided attention. The meta‐analysis revealed evidence of impairments in STM [g = 0.64, 95% confidence interval (CI) = 0.15–1.13], LTM (Hedges’ g = 0.59, 95% CI = 0.01–1.17) sustained attention (g = 0.47, 95% CI = 0.07–0.87) and psychomotor speed (Hedges’ g = 0.66, 95% CI = 0.31–1.00) during alcohol hangover.Conclusion: The research literature suggests that alcohol hangovers may involve impaired cognitive functions and performance of everyday tasks such as driving.
Purpose of the Review Comorbidity of alcohol and tobacco use is highly prevalent and may exacerbate the health effects of either substance alone. However, the mechanisms underlying this comorbidity are not well understood. This review will examine the evidence for shared neurobiological mechanisms of alcohol and nicotine comorbidity and experimental studies of the behavioural consequences of these interactions. Recent Findings Studies examining the shared neurobiology of alcohol and nicotine have identified two main mechanisms of comorbidity: (1) cross-reinforcement via the mesolimbic dopamine pathway and (2) cross-tolerance via shared genetic and nAChR interaction. Animal and human psychopharmacological studies demonstrate support for these two mechanisms of comorbidity. Summary Human behavioural studies indicate that (1) alcohol and tobacco potentiate each other’s rewarding effects and (2) nicotine reduces the sedative and intoxication effects of alcohol. Together, these findings provide a strong evidence base to support the role of the cross-reinforcement and cross-tolerance as mechanisms underlying the comorbidity of alcohol and tobacco use. Methodological concerns in the literature and recommendations for future studies are discussed alongside implications for treatment of comorbid alcohol and tobacco use.
Agomelatine is a new antidepressant with a novel profile of pharmacological action. The clinical efficacy of agomelatine has been established in major depression, but its actions on emotional bias are unknown. Consequently, the current experimental study assessed the effect of agomelatine on emotional processing in healthy volunteers using an Emotional Test Battery shown to be sensitive to serotonin and noradrenaline reuptake inhibitors. Volunteers were randomized to receive placebo, 25 mg or 50 mg of agomelatine over a 7-day period in a double-blind parallel groups design. Emotional processing (n = 48) was assessed on the morning of day 8 using the Emotional Test Battery which included facial expression recognition, emotional memory, attentional visual probe and emotion-potentiated startle. Mood and subjective state were monitored before and during treatment. Agomelatine (25 mg) decreased subjective ratings of sadness, reduced recognition of sad facial expressions, improved positive affective memory and reduced the emotion-potentiated startle response. The results show that agomelatine has more selective effects on the processing of social facial cues than conventional antidepressants, which could contribute to less blunting of emotional experience. The study highlights the potential value of volunteer models in drug development for screening and profiling of novel antidepressants.